Lupus Nephritis: Navigating Therapeutic Possibilities to Optimize Outcomes This activity is supported by an educational grant from Genentech, a member of the Roche Group.

The authors study how apolipoprotein L1 variants impact inflammation and lipid accumulation in macrophages. The findings will be useful for researchers investigating macrophage metabolism and ...

FDA Approves Benlysta Autoinjector for Pediatric Patients With Active Lupus Nephritis By Lori Solomon HealthDay ReporterMONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug ...

An immunologic biomarker shows early promise for predicting renal flare in patients with lupus nephritis.

March is Kidney Month! In November 2024, the American College of Rheumatology (ACR) released a summary of their new guidelines for the screening, treatment, and management of lupus nephritis. What is ...

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the treatment of lupus nephritis.

“In people with lupus nephritis, Gazyva demonstrated a complete renal response benefit, a meaningful clinical outcome linked to preservation of kidney function, and slowing or prevention of end-stage ...

In people with lupus nephritis who have progressive refractory disease and are approaching kidney failure, we strongly recommend kidney transplantation over dialysis.

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and ...